Based on the provided data, I cannot extract specific medications or therapies as they are not included in the source data. The trial appears to be a Phase 2 platform study for multiple therapies in Crohn’s Disease and Ulcerative Colitis patients, but the specific medications are not listed in the provided information.

If you would like a list of medications and their descriptions, please provide additional data that includes the specific treatments being studied in this clinical trial.

Ulcerative Colitis – A chronic inflammatory bowel disease that affects the large intestine (colon) and rectum. The condition causes inflammation and ulcers in the digestive tract’s innermost lining. It develops gradually and can cause ongoing symptoms including diarrhea with blood or mucus, abdominal pain, and urgency to have bowel movements. The inflammation typically starts in the rectum and can spread continuously to other parts of the colon.

Crohn’s Disease – A chronic inflammatory bowel disease that can affect any part of the digestive tract, from the mouth to the anus. Unlike ulcerative colitis, Crohn’s disease involves inflammation that can spread deep into affected tissues and can occur in patches, with healthy tissue between affected areas. The condition commonly affects the end of the small intestine and the beginning of the colon. Common symptoms include abdominal pain, diarrhea, fatigue, and reduced appetite.